|Brand name(s), other common name(s)||Arzerra®|
|Drug type||Monoclonal antibody|
|How the drug is given||Intravenously (IV)|
Ofatumumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
Side effects needing medical attention:Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.